Bilastine: in allergic rhinitis and urticaria

Area of Science:

• Pharmacology
• Allergy and Immunology
• Clinical Trials

Background:

• Bilastine is a second-generation antihistamine for allergic rhinoconjunctivitis and urticaria.
• Second-generation antihistamines aim for targeted symptom relief with reduced side effects.

Purpose of the Study:

• To evaluate the efficacy and tolerability of bilastine in allergic conditions.
• To compare bilastine's effectiveness against placebo and other antihistamines.

Main Methods:

• Phase II and III clinical trials involving patients with seasonal allergic rhinitis, perennial allergic rhinitis, and chronic urticaria.
• Symptom scores (total symptom score, nasal symptom scores, urticaria symptom scores) were measured using area under the effect curve (AUEC) and change from baseline.
• Active comparators included cetirizine, levocetirizine, and desloratadine.

Main Results:

• Bilastine significantly reduced symptoms in seasonal allergic rhinitis and chronic urticaria compared to placebo.
• No significant difference in efficacy was observed between bilastine and active comparators.
• Bilastine was not effective for perennial allergic rhinitis in one trial, potentially due to confounding factors.

Conclusions:

• Bilastine demonstrates efficacy in treating seasonal allergic rhinitis and chronic urticaria.
• Bilastine is well-tolerated, with a safety profile similar to other second-generation antihistamines.
• Further investigation may be needed for perennial allergic rhinitis treatment efficacy.